Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy
Anticancer Research · 2026
DOI: 10.21873/anticanres.18013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yasutaka Yamada und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan; yasutaka_yamada@chiba-u.jp. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Febrile Neutropenia.
Abstract (Originalsprache)
Background/Aim: Triplet therapy, combining androgen deprivation therapy (ADT), darolutamide, and docetaxel has recently emerged as the standard first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Febrile neutropenia (FN) is a major clinical issue not only as a serious infection but also as a cause for early cessation or dose reduction of chemotherapy. However, little is known regarding the predictive factors for the development of FN in patients with mHSPC receiving triplet therapy. Patients and Methods: This study enrolled 60 patients diagnosed with mHSPC across multiple institutions from 2023 to 2025. We examined clinical characteristics, treatment schedules, adverse events, and oncological outcomes. We focused particularly on the development of FN and used logistic regression analysis to investigate the predictive factors. Results: The median age was 72 years old, and 43 patients (73.3%) had high-volume disease at diagnosis. Nine patients (15%) developed FN. Multivariate logistic regression analysis identified older age [≥75, p=0.0161; hazard ratio (HR)=7.49], high-volume disease (p=0.0335), and shorter interval from ADT to docetaxel (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan; yasutaka_yamada@chiba-u.jp.
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Urology, Kimitsu Chuo Byoin, Chiba, Japan.
- Department of Urology, Chiba Rosai Hospital, Chiba, Japan.
- Department of Urology, Chibaken Saiseikai Narashino Hospital, Chiba, Japan.
Zitieren
APA
Yamada, Y., Shirafuji, T., Sato, K., Tsujino, T., Yamamoto, S., Arai, T., Sato, H., Higuchi, K., Kanesaka, M., Takeshita, N., Tamura, T., Sazuka, T., Imamura, Y., Mikami, K., Nakamura, K., Fukasawa, S., Kurozumi, A., Suzuki, N., Azuma, H., & Sakamoto, S. (2026). Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy. Anticancer Research. https://doi.org/10.21873/anticanres.18013
Vancouver
Yamada Y, Shirafuji T, Sato K, Tsujino T, Yamamoto S, Arai T, et al. Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy. Anticancer Research. 2026. doi:10.21873/anticanres.18013
BibTeX
@article{Yamada2026,
author = {Yamada, Yasutaka and Shirafuji, Tomoki and Sato, Kodai and Tsujino, Takuya and Yamamoto, Satoshi and Arai, Takayuki and Sato, Hiroaki and Higuchi, Kosuke and Kanesaka, Manato and Takeshita, Nobushige and Tamura, Takaaki and Sazuka, Tomokazu and Imamura, Yusuke and Mikami, Kazuo and Nakamura, Kazuyoshi and Fukasawa, Satoshi and Kurozumi, Akira and Suzuki, Noriyuki and Azuma, Haruhito and Sakamoto, Shinichi},
title = {Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18013}
}
EUVIMED